



30 June 2021

Sydney, Australia

## Notice of Change of Interests of Substantial Securityholder

**Sydney, 30 June 2021:** Nyrada Inc (ASX: NYR), advises, further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depository Interests (“CDIs”), a Change of Interests of a Substantial Holder in relation to Nyrada. Details of the change in CDIs (“Relevant Interests”) are as follows:

**Name of Substantial Holder of Relevant Interests:** Noxopharm Limited

**Date of change in the interests of the Substantial Holder:** 29 June 2021

**Previous and present voting power of Substantial Holder (through CHESSE Depository Nominees Pty Ltd):**

Previous notice		Present notice	
Number of CDIs	Voting power	Number of CDIs	Voting Power
33,373,245	24.09%	33,373,245	21.39%

**Present Relevant Interests:**

Holder of Relevant Interest	Registered Holdings of CDIs	Relevant Interest Number of CDIs	Voting Power
Noxopharm Limited	Noxopharm Limited	33,373,245	21.39%

- ENDS -



## About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.

[www.nyrada.com](http://www.nyrada.com)

*Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.*

### Investor & Corporate Enquiries:

Laura Vize  
Investor Relations Manager  
T: 0417 026 056  
E: [info@nyrada.com](mailto:info@nyrada.com)

### Company Secretary:

David Franks  
T: 02 8072 1400  
E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

### Media Enquiries:

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)